VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901Business Wire • 09/29/22
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV MeetingBusiness Wire • 09/21/22
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®Business Wire • 09/08/22
VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 08/08/22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial OfficerBusiness Wire • 07/12/22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022Business Wire • 06/28/22
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of GlioblastomaBusiness Wire • 06/22/22
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual MeetingBusiness Wire • 06/06/22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B VaccineBusiness Wire • 06/01/22
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022Business Wire • 05/19/22
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/09/22
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B VaccineBusiness Wire • 05/02/22
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual MeetingBusiness Wire • 04/28/22
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI's eVLP Coronavirus ProgramBusiness Wire • 04/05/22
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in AdultsBusiness Wire • 03/29/22